Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC - Université de Montpellier Accéder directement au contenu
Article Dans Une Revue Journal of Hepatology Année : 2017

Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC

Résumé

The Modified Response Evaluation Criteria in Solid Tumors (mRECIST) was developed to overcome the limitations of standard RECIST criteria in response assessment of hepatocellular carcinoma (HCC). We aimed to investigate whether objective response by mRECIST accurately predicted overall survival (OS) in patients with advanced HCC treated with systemic targeted therapies and also to preliminarily assess this end-point as a potential surrogate of OS.

Dates et versions

hal-01790263 , version 1 (11-05-2018)

Identifiants

Citer

Riccardo Lencioni, Robert Montal, Ferran Torres, Joong-Won Park, Thomas Decaens, et al.. Objective response by mRECIST as a predictor and potential surrogate end-point of overall survival in advanced HCC. Journal of Hepatology, 2017, 66 (6), pp.1166 - 1172. ⟨10.1016/j.jhep.2017.01.012⟩. ⟨hal-01790263⟩
103 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More